Flatiron Health, a NYC-based provider of oncology software, raised $175m in Series C funding.
The round was led by Roche with participation from Allen & Company, Baillie Gifford and Casdin Capital. In conjunction with the funding, Daniel O’Day, chief operating officer, Roche Pharmaceuticals, will join Flatiron Health’s Board of Directors.
Led by Nat Turner, co-founder and chief executive officer, Zach Weinberg, co-founder, president and chief operating officer, and Robert J. Green, MD, vice president, Clinical Strategy and senior medical director, Flatiron Health provides the Flatiron Health OncologyCloud™ platform, which includes electronic medical record for oncology, analytics, patient portal and integrated billing management to deliver support for cancer care providers and life science companies.
The company intends to use the funds to further invest in its software platform including enhancements across workflow optimization, infrastructure and design, new additions to value-based care solutions portfolio, designed to enable providers to participate in initiatives such as the Oncology Care Model (OCM) and other alternative payment models, release of tools and services to further support providers focused on clinical transformation.
In addition to the financing round, Roche will purchase a number of Flatiron Health’s life science offerings. The companies will also collaborate to accelerate clinical trials, advance personalized medicine and enhance patient care.